Pulmonx Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LUNG research report →
Range $5 – $7
Price Chart
About the company
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System.
- CEO
- Glendon E. French
- IPO
- 2020
- Employees
- 296
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on LUNG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $111.93M
- P/E
- -2.57
- PEG
- -0.07
- P/S
- 1.26
- P/B
- 3.24
- EV/EBITDA
- -3.14
- Div Yield
- 0.00%
- Gross Margin
- 77.42%
- Op Margin
- -44.39%
- Net Margin
- -47.93%
- ROE
- -98.23%
- ROIC
- -43.32%
Latest fiscal year · YoY change
- Revenue
- $90.50M+8.0%
- Gross Profit
- $67.14M+8.3%
- Op Income
- $-53,663,000
- Net Income
- $-54,003,000+4.2%
- EPS
- $-1.33+7.6%
- OCF Growth
- -2.9%
- FCF Growth
- +0.3%
- 52W High
- $3.25
- 52W Low
- $1.13
- 50D MA
- $2.21
- 200D MA
- $1.73
- Beta
- 0.28
- RSI (14)
- 51
- Avg Volume
- 641.52K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Pulmonx returned to year-over-year revenue growth in Q3 2026 as U.S. and international sales improved, margins held above 75%, and management reaffirmed full-year revenue guidance.· October 27, 2026
- Q3 revenue was $22.8 million, up 6% year over year, with U.S. revenue up 7% to $14.9 million and international revenue up 5% to $7.9 million.
- Gross margin improved to 76% from 75% a year ago, and management now expects full-year 2026 gross margin of about 77%.
- Operating expenses fell 18% to $24.9 million, helping reduce net loss to $8.4 million and adjusted EBITDA loss to $3.5 million.
- Management reiterated full-year 2026 revenue guidance of $90 million to $92 million and said Q4 should continue the return-to-growth trend.
- AeriSeal remains a longer-term market expansion opportunity, with CONVERT II enrollment on track to finish in the back half of next year.
Pulmonx reported Q3 2026 total worldwide revenue of $22.8 million, up 6% from $21.5 million in the prior-year period. U.S. revenue was $14.9 million, up 7% from $14.0 million, and international revenue was $7.9 million, up 5% from $7.5 million. Gross margin was 76% versus 75% last year. Total operating expenses were $24.9 million, down 18% from $30.4 million. Net loss was $8.4 million, or $0.19 per share, versus a net loss of $14.0 million, or $0.34 per share, a year ago. Adjusted EBITDA loss was $3.5 million versus $8.2 million last year. Cash and cash equivalents ended at $52.7 million, down $3.2 million from 06/30/2026. For full-year 2026, management reiterated revenue guidance of $90 million to $92 million, expects gross margin of approximately 77%, operating expenses of $108 million to $109 million, and cash burn of roughly $22 million.
Glenn French framed the quarter as a meaningful inflection, saying the company has returned to revenue growth and is seeing its ‘strategy in action.’ He emphasized the near-to-far commercial framework, stronger U.S. execution, and a rebuilt sales organization with substantially all open U.S. sales positions filled. He also highlighted AeriSeal as a long-term TAM expansion opportunity and said the company is increasingly confident in sustaining growth and operating leverage.
Derrick Sung focused on the improving financial profile: Q3 revenue of $22.8 million, gross margin of 76%, operating expenses of $24.9 million, net loss of $8.4 million, and adjusted EBITDA loss of $3.5 million. He said full-year operating expenses are now expected to be $108 million to $109 million, including about $14 million of stock-based compensation, and full-year cash burn is expected to be roughly $22 million, about 30% lower than 2025. He also noted $52.7 million in cash and cash equivalents at quarter-end, the credit facility restructuring that extends debt maturity to 2031, and access to an additional $20 million in undrawn capital subject to revenue milestones.
Analysts focused on what drove the U.S. outperformance, where management said there was no single factor but rather broader improvement from a fuller sales bench, better execution, and procedure opportunities getting completed. Questions also centered on the productivity curve of newer reps; management said tenure is still relatively short but that training changes and promotions from junior reps are helping, and that one region led by former TAMs was the top dollar-growth region. On 2027, management declined to provide guidance but said it is comfortable with current consensus and remains committed to double-digit growth over time, while clarifying China is only about 2% of business when it returns and that AeriSeal’s meaningful Europe revenue contribution is more likely in 2028 than 2027.
The strongest bull case from this call is that Pulmonx has reestablished top-line growth while simultaneously compressing costs and improving leverage. Management described stronger U.S. execution, fuller sales coverage, better digital efficiency, and healthy international growth excluding China, while maintaining gross margins above 75%. They also sounded confident that the current cost structure can support further growth and that AeriSeal could expand the addressable market over time.
The main bear case is that the business is still early in its recovery and depends on a relatively new sales organization gaining productivity. Management acknowledged short average tenure in the U.S. sales force and said it is difficult to attribute growth to any single driver, which suggests the rebound may still be fragile. China remains lumpy and distributor-based, and AeriSeal is not expected to drive material revenue until later, leaving near-term growth reliant on execution in the core business.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.1%
- Shares Outstanding
- 43.55M
- Float Shares
- 37.91M
of shares held by institutions
112 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Primecap Management Co | 4.41M | ▼ 203.90K |
| Morgan Stanley | 3.26M | ▲ 332.93K |
| Soleus Capital Management, L.P. | 3.09M | ▲ 300.00K |
| Vanguard Group Inc | 2.54M | ▲ 298.35K |
| Vanguard Capital Management LLC | 1.70M | ▲ 66.52K |
| Exoduspoint Capital Management, LP | 1.31M | ▲ 90.19K |
| Almitas Capital LLC | 1.08M | ▲ 15.84K |
| Parkman Healthcare Partners LLC | 853.99K | ▲ 207.42K |
| Blackrock, Inc. | 765.56K | ▼ 116.93K |
| Braidwell LP | 752.54K | 0 |
| D. E. Shaw & Co., Inc. | 740.87K | ▲ 413.34K |
| Marshall Wace, Llp | 660.47K | ▲ 429.73K |
Held by 35 ETFs
Biggest fund positions in LUNG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | French Glendon E. III | sell | 4,098 |
| Sep 1, 26 | French Glendon E. III | sell | 37,784 |
| Sep 1, 26 | Radhakrishnan Srikanth | sell | 2,643 |
| Sep 1, 26 | Radhakrishnan Srikanth | sell | 2,121 |
| Sep 1, 26 | Radhakrishnan Srikanth | sell | 3,618 |
| Sep 1, 26 | Radhakrishnan Srikanth | sell | 5,863 |
| Sep 1, 26 | Lehman David Aaron | sell | 3,807 |
| Sep 1, 26 | Lehman David Aaron | sell | 2,224 |
| Sep 1, 26 | Lehman David Aaron | sell | 3,476 |
| Sep 1, 26 | Lehman David Aaron | sell | 4,827 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LUNG coverage
Recent articles, reports, and earnings notes.
No research on LUNG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LUNG report →Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference
globenewswire.com · Nov 18
Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
globenewswire.com · Nov 17
Pulmonx: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 8
All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy
zacks.com · Oct 30
Pulmonx to Participate in Upcoming Investor Conferences
globenewswire.com · Oct 28
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Oct 27
What Pulmonx (LUNG) Said on Its Q3 Earnings Call
marketbeat.com · Oct 27
Pulmonx Corporation (LUNG) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.